Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Fundamental Monetary Guidance for Going into Business - 2Astronomers discover never-before-seen celestial object: "Cloud 9"
- 3Iran begins cloud seeding to induce rain amid historic drought
- 4Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- 5Fundamental Home Machines: An Easy to understand Determination Guide
- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- Investigating Design and Individual Style: Track down Your Remarkable Look
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay?
- Rocket shines under the northern lights | Space photo of the day for March 25, 2026
- Exclusive new photos from 'Michael' biopic show Jaafar Jackson as King of Pop
- Three arrested in Paris after attempted bomb attack outside Bank of America
- Figure out How to Acquire Rewarding Open Record Rewards
